EP3709871A4 - Zusammensetzungen und verfahren zur intensivierung visueller funktionen - Google Patents

Zusammensetzungen und verfahren zur intensivierung visueller funktionen Download PDF

Info

Publication number
EP3709871A4
EP3709871A4 EP18875857.7A EP18875857A EP3709871A4 EP 3709871 A4 EP3709871 A4 EP 3709871A4 EP 18875857 A EP18875857 A EP 18875857A EP 3709871 A4 EP3709871 A4 EP 3709871A4
Authority
EP
European Patent Office
Prior art keywords
intensifying
procedures
compositions
visual functions
visual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18875857.7A
Other languages
English (en)
French (fr)
Other versions
EP3709871A1 (de
Inventor
Ehud Y. Isacoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley, University of California San Diego UCSD filed Critical University of California
Publication of EP3709871A1 publication Critical patent/EP3709871A1/de
Publication of EP3709871A4 publication Critical patent/EP3709871A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18875857.7A 2017-11-13 2018-11-13 Zusammensetzungen und verfahren zur intensivierung visueller funktionen Pending EP3709871A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762585237P 2017-11-13 2017-11-13
US201762589476P 2017-11-21 2017-11-21
US201862641783P 2018-03-12 2018-03-12
PCT/US2018/060669 WO2019094904A1 (en) 2017-11-13 2018-11-13 Compositions and methods for enhancing visual function

Publications (2)

Publication Number Publication Date
EP3709871A1 EP3709871A1 (de) 2020-09-23
EP3709871A4 true EP3709871A4 (de) 2021-12-01

Family

ID=66438686

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18875857.7A Pending EP3709871A4 (de) 2017-11-13 2018-11-13 Zusammensetzungen und verfahren zur intensivierung visueller funktionen

Country Status (12)

Country Link
US (2) US10745453B2 (de)
EP (1) EP3709871A4 (de)
JP (2) JP2021502331A (de)
KR (1) KR20200087782A (de)
CN (1) CN111417339A (de)
AU (1) AU2018365175A1 (de)
BR (1) BR112020009329A2 (de)
CA (1) CA3080146A1 (de)
IL (1) IL274176A (de)
MX (1) MX2020004643A (de)
SG (1) SG11202003778QA (de)
WO (1) WO2019094904A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269352A (zh) * 2019-06-27 2022-04-01 佛罗里达大学研究基金会 用透明质酸增强aav介导的眼组织转导
CN111445483B (zh) * 2020-03-25 2024-11-05 哈尔滨医科大学 一种智能体双模态视觉行为监控系统
US20240197913A1 (en) * 2021-04-20 2024-06-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for treating retinal degenerative disorders
JP2024520558A (ja) * 2021-05-26 2024-05-24 スパーリングヴィジョン Ｇタンパク質ゲート－ｋ＋チャネルを介した桿体－錐体ジストロフィー（ｒｃｄ）における光感受性の増強
WO2023196746A1 (en) * 2022-04-04 2023-10-12 The Regents Of The University Of California Compositions and methods for enhancing visual function
US20240266008A1 (en) * 2023-02-01 2024-08-08 Unlearn.AI, Inc. Systems and Methods for Designing Augmented Randomized Trials
CN118791624B (zh) 2023-04-11 2026-04-03 苏州星明优健生物技术有限公司 用于治疗视网膜神经退行性疾病的新型gpcr嵌合视蛋白
WO2025022144A1 (en) * 2023-07-26 2025-01-30 Sorbonne Universite Chimeric promoter for targeted expression in aii amacrine cells
CN120230798A (zh) * 2023-12-29 2025-07-01 上海朗昇生物科技有限公司 用于视网膜基因递送的重组腺相关病毒载体及其应用
WO2025214507A1 (zh) * 2024-09-03 2025-10-16 中眸医疗科技(武汉)有限公司 新型光敏感通道蛋白vr3.0及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20080260744A1 (en) * 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
JP5870400B2 (ja) * 2010-04-15 2016-03-01 シアトル ジェネティクス，インコーポレーテッド 標的化ピロロベンゾジアゼピンコンジュゲート
US10112984B2 (en) * 2011-06-24 2018-10-30 Haagstreit Medtech Ag Light-sensitive chimeric GPCR protein
GB201403260D0 (en) * 2014-02-25 2014-04-09 Univ Manchester Treatment of retinal degeneration using gene therapy
EP3800191B1 (de) * 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Zusammensetzungen und verfahren zur verbesserten genexpression in zapfenzellen
CN108347932B (zh) * 2015-02-20 2022-09-13 衣阿华大学研究基金会 用于治疗遗传性眼病的方法和组合物
WO2016149664A1 (en) * 2015-03-18 2016-09-22 University Of Florida Research Foundation, Inc. Methods and compositions for restoration of cone function in bcm
WO2017055421A1 (en) * 2015-09-29 2017-04-06 Ist Austria Pancreatic beta-cell proliferation methods and device
EP3570895A1 (de) * 2017-01-17 2019-11-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur expression eines bestimmten polynukleotids in den zapfen-fotorezeptoren

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein

Also Published As

Publication number Publication date
CA3080146A1 (en) 2019-05-19
US10745453B2 (en) 2020-08-18
IL274176A (en) 2020-06-30
CN111417339A (zh) 2020-07-14
JP2021502331A (ja) 2021-01-28
EP3709871A1 (de) 2020-09-23
JP2023179527A (ja) 2023-12-19
MX2020004643A (es) 2021-01-29
WO2019094904A1 (en) 2019-05-16
KR20200087782A (ko) 2020-07-21
AU2018365175A1 (en) 2020-05-21
US20190169244A1 (en) 2019-06-06
US20200339641A1 (en) 2020-10-29
SG11202003778QA (en) 2020-05-28
RU2020119546A3 (de) 2022-03-23
BR112020009329A2 (pt) 2020-10-13
RU2020119546A (ru) 2021-12-15

Similar Documents

Publication Publication Date Title
EP3638289A4 (de) Pde5-zusammensetzungen und verfahren zur immuntherapie
EP3490622C0 (de) Verfahren und zusammensetzungen zur wundheilung
EP3507603C0 (de) Zusammensetzungen und verfahren zur verbesserten fluoreszenz
EP3600271A4 (de) Verfahren und zusammensetzungen zur verbesserung der gesundheit
EP3723776A4 (de) Zusammensetzungen und verfahren zur unterdrückung pathogener organismen
EP3704254A4 (de) Cas12c-zusammensetzungen und verfahren zur verwendung
EP3638096A4 (de) Verfahren und systeme zur oct-geführten glaukomchirurgie
EP3531945A4 (de) Chirurgisches instrument und verfahren
EP3714845A4 (de) Shunt-katheter zur verbesserten verankerung und katheter
EP3534815A4 (de) Verfahren und vorrichtungen zur punktierung von gewebe
EP3217046C0 (de) Anordnungen und zugehörige verfahren
EP4083203C0 (de) Zusammensetzungen und verfahren zur verringerung von okularer neovaskularisation
EP3723511A4 (de) Zusammensetzungen und verfahren zur bewahrung von gewichtsabnahme
EP3191005C0 (de) Systeme und verfahren zur bildgebung und manipulation von gewebe
EP3784258A4 (de) Künstliche exosomenzusammensetzung und verwandte verfahren
EP3601538A4 (de) Ank- und il-12-zusammensetzungen und verfahren
EP3484469A4 (de) Zusammensetzungen und verfahren zur verstärkung von antimikrobiata
EP3720378C0 (de) Katheter und verfahren zur katheteranordnung
EP3658179C0 (de) Verfahren und zusammensetzungen für heterologe reprna-immunisierungen
IL264613B (en) Hemostatic preparations and methods for their preparation
EP3640333A4 (de) System und verfahren zur geneditierung
EP3265096C0 (de) Ophthalmische zusammensetzungen und verfahren zur verwendung davon
IL274176A (en) Preparations and methods for improving visual function
EP3558329A4 (de) Zusammensetzungen und verfahren zur hemmung von anfällen
EP3687628A4 (de) Zusammensetzungen und verfahren zur hemmung von acss2

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200507

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40033915

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20211104

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/72 20060101ALI20211028BHEP

Ipc: A61K 48/00 20060101ALI20211028BHEP

Ipc: A61B 5/00 20060101AFI20211028BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240206